3-(N-2-phenylthioethyl-N-methylamino)-1-hydroxypropane-1,1-diphosphonic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: 3-(N-2-phenylthioethyl-N-methylamino)-1-hydroxypropane-1,1-diphosphonic acid
• 英文别名: [1-Hydroxy-3-[methyl(2-phenylsulfanylethyl)amino]-1-phosphonopropyl]phosphonic acid
• 化学式: C₁₂H₂₁NO₇P₂S
• 分子量: 385.315
• InChiKey: QWCNOXMFNSYEKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  164
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  3-[Methyl-(2-phenylsulfanyl-ethyl)-amino]-propionic acid 在 磷酸 、 三氯化磷 作用下， 以 氯苯 为溶剂， 反应 3.0h， 以30%的产率得到3-(N-2-phenylthioethyl-N-methylamino)-1-hydroxypropane-1,1-diphosphonic acid
  参考文献：
  名称：

  Highly Potent Geminal Bisphosphonates. From Pamidronate Disodium (Aredia) to Zoledronic Acid (Zometa)

  摘要：

  Bisphosphonates (BP) are pyrophosphate analogues in which the oxygen in P-O-P has been replaced by a carbon, resulting in a metabolically stable P-C-P structure. Pamidronate (1b, Novartis), a second-generation BP, was the starting point for extensive SAR studies. Small changes of the structure of pamidronate lead to marked improvements of the inhibition of osteoclastic resorption potency. Alendronate (1c, MSD), with an extra methylene group in the N-alkyl chain, and olpadronate (1h, Gador), the N,N-dimethyl analogue, are about 10 times more potent than pamidronate. Extending one of the N-methyl groups of olpadronate to a pentyl substituent leads to ibandronate (1k, Roche, Boehringer-Mannheim), which is the most potent close analogue of pamidronate. Even slightly better antiresorptive potency is achieved with derivatives having a phenyl group linked via a short aliphatic tether of three to four atoms to nitrogen, the second substituent being preferentially a methyl group (e.g., 4g, 4j, 5d, or 5r). The most potent BPs are found in the series containing a heteroaromatic moiety (with at least one nitrogen atom), which is linked via a single methylene group to the geminal bisphosphonate unit. Zoledronic acid (6i), the most potent derivative, has an ED50 of 0.07 mg/kg in the TPTX in vivo assay after sc administration. It not only shows by far the highest therapeutic ratio when comparing resorption inhibition with undesired inhibition of bone mineralization but also exhibits superior renal tolerability. Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa. The results of the clinical trials indicate that low doses are both efficacious and safe for the treatment of tumor-induced hypercalcemia, Paget's disease of bone, osteolytic metastases, and postmenopausal osteoporosis.

  DOI：

  10.1021/jm020819i

文献信息

• [EN] QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE<br/>[FR] QUINOLÉINES EN TANT QU'INHIBITEURS DE LA FARNÉSYL PYROPHOSPHATE SYNTHASE
  申请人：NOVARTIS AG

  公开号：WO2009106586A1

  公开（公告）日：2009-09-03

  The invention relates to a compound of formula (I) wherein the substituents are as described in the specification, which are useful as farnesyl pyrophosphate synthase modulators, e.g. in the treatment of proliferative diseases, to methods of manufacturing such compounds and to intermediates thereof.

  本发明涉及式(I)化合物，其中取代基如说明书中所述，这些化合物作为法尼基焦磷酸合酶调节剂是有用的，例如在增殖性疾病的治疗中，涉及制造这些化合物的方法及其中间体。
• Method of administering bisphosphonates
  申请人：——

  公开号：US20030181421A1

  公开（公告）日：2003-09-25

  Bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, can be used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, wherein the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.

  双膦酸盐，特别是更强效的N-双膦酸盐，如左氧磷酸和衍生物，可以通过间歇性给药获得令人满意的结果，长期抑制骨质疏松等异常增加骨转换的情况中的骨吸收，例如骨质疏松症，其中双膦酸盐给药之间的间隔时间比以前认为适当的更长，例如至少大约6个月或更少频繁的给药间隔。
• Use of bisphosphonates for pain treatment
  申请人：——

  公开号：US20040063670A1

  公开（公告）日：2004-04-01

  A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumour patient or a patient suffering from an inflammatory disease, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient.

  一种用于治疗疼痛的方法，特别是用于需要这种治疗的患者，例如骨质疏松症或骨质疏松症患者、肿瘤患者或患有炎症性疾病的患者的镇痛或抗痛觉过敏治疗，包括向患者施用有效量的双膦酸盐，例如唑来膦酸或其盐或水合物。
• [EN] SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE SALICYLIQUE EN TANT QU'INHIBITEURS DE L'ACTIVITÉ FARNÉSYLPYROPHOSPHATE SYNTHASE
  申请人：NOVARTIS AG

  公开号：WO2010043584A1

  公开（公告）日：2010-04-22

  The invention relates to the use of and mainly novel compounds of the formula (I) wherein the moieties are as defined in the description, which are useful as farnesyl pyrophosphate synthase modulators and e.g. in the treatment of proliferative diseases.

  该发明涉及使用主要是新颖化合物的公式（I），其中基团如描述中定义的，这些化合物可用作法尼基焦磷酸合酶调节剂，例如用于治疗增殖性疾病。
• Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
  申请人：CIBA-GEIGY AG

  公开号：EP0550385A1

  公开（公告）日：1993-07-07

  Die Erfindung betrifft peroral zu verabreichende pharmazeutische Zusammensetzungen enthaltend (a) pharmazeutisch verwendbare Methandiphosphonsäure-Derivate, z.B. solche von der Formel I, worin R₁ und R₂ wie in der Beschreibung angegeben definiert sind, oder pharmazeutisch annehmbare Salze davon, (b) makrozyklische Polyether der Formel II worin X&sub1;-X&sub4; unabhänig voneinander Carboxy, Carbamoyl oder N-mono- oder N,N-di-substituiertes Carbamoyl bedeuten, und (c) gegebenenfalls pharmazeutisch annehmbare Hilfsstoffe. Sie werden in an sich bekannter Weise hergestellt.

  这项发明涉及口服给药的药物组合物，包含（a）可用于制药的甲烷二膦酸衍生物，例如，公式I中R₁和R₂如所述定义的衍生物，或其药学上可接受的盐，（b）公式II中的大环聚醚，其中X&sub1;-X&sub4;分别表示羧基，氨基甲酰或N-单取代或N，N-二取代的氨基甲酰，以及（c）可选的药学上可接受的辅料。它们是以已知的方式制备的。